Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity

Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity

Although gemcitabine plus cisplatin is the gold standard chemotherapy regimen for advanced cholangiocarcinoma, the response rate has been disappointing. This study aims to investigate a novel therapeutic regimen [gemcitabine plus everolimus (rad001), an mTOR inhibitor] for cholangiocarcinoma. Gemcit...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Gigin Lin, Kun-Ju Lin, Frank Wang, Tse-Ching Chen, Tzu-Chen Yen, Ta-Sen Yeh
Formatua: Artikulua
Hizkuntza:English
Argitaratua: The Company of Biologists 2018-08-01
Saila:Disease Models & Mechanisms
Gaiak:
Cholangiocarcinoma
Choline kinase
FAS
Gemcitabine
Rad001
Sarrera elektronikoa:http://dmm.biologists.org/content/11/8/dmm033050

Internet

http://dmm.biologists.org/content/11/8/dmm033050

Antzeko izenburuak